On August 13, 2025, IceCure Medical Ltd. reported its financial results for the six months ended June 30, 2025. Revenue for the period was $1,250,000, a decrease from $1,754,000 in the first half of 2024. Gross profit was $349,000, down from $799,000, resulting in a gross margin of 28%. The net loss for the six months was $6,952,000, or $0.12 per share, compared to $6,690,000, or $0.14 per share, in the prior year.
The company noted that over $200,000 in product sales scheduled for Q2 2025 were delayed to Q3 due to the Israel-Iran conflict in June 2025, impacting the reported revenue. Despite this, IceCure successfully closed a $10 million rights offering on August 1, 2025, which was approximately two times oversubscribed. This significantly strengthened the company's balance sheet, with plans to repay a $2 million bridge loan to its major shareholder in August 2025.
IceCure also provided an update on its U.S. FDA marketing authorization request for ProSense® in early-stage low-risk breast cancer. The post-market study plan was fully submitted to the FDA, and the company is in ongoing dialogue with the agency, providing additional requested information. IceCure remains optimistic that approval will be granted before year-end 2025, addressing an estimated 46,000 patients annually in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.